A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer

What is the purpose of this trial?

This study is designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with Stage IB, II, or IIIA NSCLC who are eligible for surgical resection with curative intent. Neoadjuvant therapy will consist of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy will consist of up to 12 months of atezolizumab in participants who demonstrate clinical benefit with neoadjuvant therapy.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Genentech, Inc.

Dates: 05/03/2017 - 07/31/2023

Last Updated: 05/17/2017

Study HIC#: 1607018082

Get Involved

For more information about this study, contact:
Kira Fitzsimons Pavlik
+1 203-737-2587
kira.pavlik@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image